{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T14:50:34Z","timestamp":1781967034379,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Paul and Ruby Tsai Family Hypertrophic Cardiomyopathy Research Fund"},{"name":"Mayo Clinic Windland Smith Rice Sudden Cardiac Death Genomics Laboratory"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypertrophic cardiomyopathy (HCM) is a heritable cardiac disorder characterized by increased left ventricular (LV) wall thickness, often leading to heart failure (HF). The role of cardiovascular magnetic resonance (CMR) imaging in predicting new onset of HF symptoms in patients with HCM remains unknown. This study aimed to identify CMR predictors of new-onset HF symptoms in individuals with HCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was a single-centre retrospective cohort study of HCM patients treated at a tertiary referral centre in the USA who underwent CMR examination between 1998 and 2018, had no HF symptoms at baseline CMR, and at least 1 year of follow-up. Clinical data were collected by review of electronic medical records, and CMR images were analyzed by a blinded expert cardiac radiologis. The primary outcome was new onset of HF symptoms, defined as New York Heart Association (NYHA) class \u2265 II at follow-up. Kaplan\u2013Meier analyses and Cox proportional hazard analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1462 patients diagnosed with HCM who had at least 1 CMR, 276 HCM patients without HF symptoms (average age 52.7 years, 33.3% female),median maximum left ventricular (LV) wall thickness was 19\u2005mm ([IQR] 17\u201322) with a and median LV ejection fraction of 71% (IQR 66\u201377). Late gadolinium enhancement was detected in 56.2%) patients (60.7% had mild; 30.7% moderate; 8.6% severe). During a median follow-up period of 6.3 years, 93 patients developed HF symptoms (NYHA class II in 56 (60.2%); class III in 31 (33.3%); and class IV in 6 (6.5%). Multivariable analysis adjusted for age showed that LA enlargement (HR 1.626; 95% CI 1.01\u20132.62; P = .045) and LV mass index (HR 1.014; 95% CI 1.007\u20131.022; P\u2264 .001) and sex (HR 1.7; 95% CI 1.074\u20132.691; P = .023) were independent predictors of new onset of HF symptoms in patients with HCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nearly half of the patients with HCM developed HF symptoms within 6.3 years. Left atrial enlargement, LV mass index, and sex were independent predictors of new onset of HF symptoms in HCM patients. These findings emphasize the value of CMR in HF risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag160","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T11:40:33Z","timestamp":1780746033000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiac magnetic resonance imaging parameters predict new-onset symptoms of heart failure in hypertrophic cardiomyopathy"],"prefix":"10.1093","volume":"13","author":[{"given":"Danuzia S","family":"da Silva","sequence":"first","affiliation":[{"name":"Department of Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Karlinski","family":"Vizentin","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuri Ferreira","family":"Felix","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Maanja","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, Karolinska University Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simmy A","family":"Lahori","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan S","family":"Pasupathy","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Health Information Sciences, University of Illinois-Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve R","family":"Ommen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B","family":"Geske","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Giudicessi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A","family":"Araoz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Ackerman","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]},{"name":"Department of Radiology, Mayo Clinic , Rochester, MN ,","place":["USA"]},{"name":"Department of Pediatric and Adolescent Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide M","family":"Arruda-Olson","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-2003","authenticated-orcid":false,"given":"J Martijn","family":"Bos","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN ,","place":["USA"]},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic , 200 First Street SW, Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2026062010013119800_xvag160-B1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jchf.2018.02.010","article-title":"Hypertrophic cardiomyopathy: clinical update","volume":"6","author":"Geske","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026062010013119800_xvag160-B2","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/S0140-6736(21)01205-8","article-title":"Hypertrophic cardiomyopathy: a practical approach to guideline directed management","volume":"398","author":"Ommen","year":"2021","journal-title":"Lancet"},{"key":"2026062010013119800_xvag160-B3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: a position paper from the heart failure association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026062010013119800_xvag160-B4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical Spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026062010013119800_xvag160-B5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1161\/CIRCULATIONAHA.104.507723","article-title":"Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy","volume":"112","author":"Rickers","year":"2005","journal-title":"Circulation"},{"key":"2026062010013119800_xvag160-B6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jcmg.2017.08.005","article-title":"Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy","volume":"10","author":"Patel","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026062010013119800_xvag160-B7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12968-021-00720-9","article-title":"Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation","volume":"23","author":"Raphael","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026062010013119800_xvag160-B8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10554-017-1263-3","article-title":"CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase","volume":"34","author":"Cheng","year":"2018","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026062010013119800_xvag160-B9","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/CIR.0000000000000937","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2026062010013119800_xvag160-B10","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2026062010013119800_xvag160-B11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1148\/radiol.10090526","article-title":"Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging","volume":"258","author":"Harrigan","year":"2011","journal-title":"Radiology"},{"key":"2026062010013119800_xvag160-B12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12916-021-02219-7","article-title":"Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med"},{"key":"2026062010013119800_xvag160-B13","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jchf.2023.07.004","article-title":"Advanced heart failure therapies for hypertrophic cardiomyopathy: state-of-the-art review and an updated analysis from UNOS","volume":"11","author":"Liang","year":"2023","journal-title":"J Am Coll Cardiol HF"},{"key":"2026062010013119800_xvag160-B14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/01.CIR.0000117098.75727.D8","article-title":"Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy","volume":"109","author":"Maron","year":"2004","journal-title":"Circulation"},{"key":"2026062010013119800_xvag160-B15","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-type natriuretic peptide and survival in hypertrophic cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026062010013119800_xvag160-B16","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s11886-024-02095-6","article-title":"Hypertrophic cardiomyopathy: from medical treatment to advanced heart failure therapies","volume":"26","author":"Mazur","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"2026062010013119800_xvag160-B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285887","article-title":"Role of cardiovascular magnetic resonance imaging and cardiopulmonary exercise test in predicting composite clinical outcomes in patients with hypertrophic cardiomyopathy","volume":"18","author":"Hwang","year":"2023","journal-title":"PLoS One"},{"key":"2026062010013119800_xvag160-B18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2012.03.076","article-title":"Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy","volume":"60","author":"Todiere","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026062010013119800_xvag160-B19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jchf.2022.08.022","article-title":"Comparison of demographic, clinical, biochemical, and imaging findings in hypertrophic cardiomyopathy prognosis: a network meta-analysis","volume":"11","author":"Georgiopoulos","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026062010013119800_xvag160-B20","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.jcmg.2021.03.032","article-title":"Maximal wall thickness measurement in hypertrophic cardiomyopathy: biomarker variability and its impact on clinical care","volume":"14","author":"Captur","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026062010013119800_xvag160-B21","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.amjcard.2006.05.013","article-title":"Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian registry for hypertrophic cardiomyopathy)","volume":"98","author":"Nistri","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026062010013119800_xvag160-B22","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.echo.2009.05.003","article-title":"The relationship of left atrial volume and left atrial pressure in patients with hypertrophic cardiomyopathy: an echocardiographic and cardiac catheterization study","volume":"22","author":"Geske","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"2026062010013119800_xvag160-B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-981-95-0313-1_3","volume-title":"Navigating Cardiology's Future","author":"Amir Ghaffari","year":"2025"},{"key":"2026062010013119800_xvag160-B24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.017174","article-title":"Prognostic value of myocardial T1 mapping for predicting adverse events in hypertrophic cardiomyopathy","volume":"18","author":"Wang","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026062010013119800_xvag160-B25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ejhf.3461","article-title":"Aficamten in non-obstructive hypertrophic cardiomyopathy: unlocking new horizons?","volume":"27","author":"Rossi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026062010013119800_xvag160-B26","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/ejhf.3372","article-title":"Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: a 36-week analysis from FOREST-HCM","volume":"26","author":"Masri","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026062010013119800_xvag160-B27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag160\/68500370\/xvag160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag160\/68500370\/xvag160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag160\/68500370\/xvag160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T14:01:39Z","timestamp":1781964099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag160\/8704672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,9]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag160","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"xvag160"}}